Introduction
Hodgkin Lymphoma (HL) is one of the most commonly occurring malignancies in adolescents and young adults, curable in the majority of cases. Unfortunately, a subgroup of patients do not enter remission with front line therapy or relapse after initial response to therapy (R/R cHL). In such cases, treatment options are different regimens of chemotherapy, radiotherapy, high-dose chemotherapy plus autologous stem cell transplantation (HDCT/ASCT), and immunotherapy1,2. Many regimens have been proposed1 and recently novel agents are increasingly involved in order to achieve a better response without increasing the toxicity burden. Brentuximab Vedotin (BV) is an antibody-drug conjugate combining the anti-CD30 monoclonal antibody with the monomethyl auristatin-E. Studies are evaluating the combination of BV with classical regimens mainly in adults, while limited is the experience in paediatrics.
Recently a phase II study3 investigated for the first time BV plus the DHAP regimen as salvage therapy in adults, with encouraging results. The experience with this regimen in children or adolescent has not been described so far.